Population IV, CD4+CD45RA−Foxp3− activated effector T cells, was increased in all MS (65.85 ± 11.02%) compared to HD (46.42 ± 14.45%) (p < 0.000001) (Fig. 2D). Here, CD4 is linked to myeloid sarcoma.